Primecap Management Co. CA Purchases New Shares in Repligen Corporation $RGEN

Primecap Management Co. CA acquired a new stake in Repligen Corporation (NASDAQ:RGEN) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 323,268 shares of the biotechnology company’s stock, valued at approximately $44,107,000. Primecap Management Co. CA owned approximately 0.57% of Repligen as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also modified their holdings of RGEN. Measured Wealth Private Client Group LLC acquired a new stake in shares of Repligen during the 3rd quarter valued at about $29,000. Rachor Investment Advisory Services LLC acquired a new position in Repligen in the 4th quarter worth about $33,000. Los Angeles Capital Management LLC acquired a new position in Repligen in the 4th quarter worth about $36,000. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Repligen in the second quarter valued at approximately $52,000. Finally, Farther Finance Advisors LLC raised its position in Repligen by 61.8% during the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 128 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Performance

Shares of Repligen stock opened at $180.30 on Thursday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. Repligen Corporation has a one year low of $100.99 and a one year high of $188.73. The company has a market cap of $10.18 billion, a PE ratio of 246.99, a P/E/G ratio of 3.32 and a beta of 1.03. The business has a 50-day simple moving average of $150.11 and a 200-day simple moving average of $132.51.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. During the same period last year, the business earned $0.26 EPS. The company’s revenue was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, equities research analysts forecast that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Insiders Place Their Bets

In other Repligen news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the sale, the chief financial officer owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on RGEN shares. JPMorgan Chase & Co. lifted their price objective on Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Wolfe Research assumed coverage on shares of Repligen in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price objective for the company. Benchmark raised Repligen from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a research note on Tuesday, July 7th. Royal Bank Of Canada started coverage on shares of Repligen in a research report on Thursday, May 14th. They set an “outperform” rating and a $160.00 price target for the company. Finally, Zacks Research raised Repligen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $166.43.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.